Replies to post #2436 on Bio Path Holdings Inc (BPTH)

[dmoffat]

Wow, more of the same. Not really surprised. This company cannot be taken seriously by big money investors when they listen to a presentation like that. I need a psychiatric evaluation for sticking it out this long since I have listened to presentations like that for the last 4 years and still had hope. Big change needs to happen or nothing will get better.

[Snug9]

SJ, In my earlier post the major investor I was referring to is Herb Allen of Allen & Co., one of the most influential investment managers in the world. My BPTH insider told me a couple of years ago that Allen was interested in helping with BPTH and approached Peter who just blew him off. If it's true, as BrettJ states, and I have no reason to assume he is not correct, that members of the Moonshot project have also now been rejected by BPTH this is unconscionable. Peter doesn't understand that his responsibility is to the shareholders (owners) not to Peter Nielsen. I have to say, I have worked with some great Board Chairmen and CEO's during my career and Peter is not one of them. Again I ask how do we mount a shareholder rebellion? Has anyone had any experience with a rebellion? Shareholders have to feel like the guy riding the atomic bomb to the ground in "Dr. Strangelove".
By the way, Juno Therapauedics was formed in 2013 to bring autoimmune CAR-T cancer drugs to the market. I read just yesterday that they expect to have a product in the market place by 2018. 5 years? They are expected to become a leader in cancer treatments although I will say they are having their problems. That's what a real company does.

[Gpheart2016]

SJ, the recent presentation by PN mentioned four test sites for the phase ii study. The clinical trials website lists only three sites: MD Anderson, Baylor Scott White, and U of Kansas. I think the fourth site was previously listed in NY? Maybe Cornell but they may have dropped out. Do you know more?